chicanary never ends
gizzy. You are clueless. Since when does book value have anything to do with a start up biotech? They trade on future revenue streams, not on what's on their books, which is nothing.
The products have gone no where. Tavaborole won't compete in the market and AN2728 is a year away. This is a shorts heaven stock. Pumped up on a little money from the Gates foundation.
Book value is the only thing we have to evaluate biotech stocks.
This stock will settle down to mid $5.00 range and then we shall see.
Take your profits while you can. This is a turd.
Sentiment: Strong Sell